We possess end-to-end CAR-T manufacturing capabilities, enabling rapid screening of antibodies against novel targets, their subsequent cloning into plasmid vectors for lentiviral packaging, and final preparation of functionally validated CAR-T cells.

Traditional CAR-T cell manufacturing requires three major steps—ex vivo activation, viral transduction, and expansion culture—typically spanning two weeks. In contrast, the rapid CAR-T manufacturing platform integrates these steps into a single streamlined process, enabling complete cell preparation within approximately 24 hours. This breakthrough significantly enhances production efficiency, shortens patients’ waiting time, and mitigates the risk of disease progression. Furthermore, CAR-T cells generated via this platform exhibit a less differentiated phenotype, reduced exhaustion markers, and enhanced tumor-killing activity. The condensed production timeline also lowers personnel and facility costs, ultimately improving the affordability and accessibility of CAR-T therapies.

1. γδ T-cell platform: γδT cells possess broad-spectrum tumor recognition and cytotoxicity capabilities. Critically, γδT cells are MHC-unrestricted in target antigen recognition, thereby eliminating the risk of graft-versus-host disease (GVHD). We have established large-scale γδ T-cell expansion platform, and developed off-the-shelf CAR-γδ T-cell therapeutic product.

2. Gene-edited allogeneic αβ T-cell platform: We use CRISPR-based gene editing technology to modify healthy donor-derived T cells, by targeting immune rejection-related genes and T-cell inhibitory genes. This dual editing strategy significantly reduces host immune rejection while enhancing tumor-killing potency.

To overcome the limitations of autologous CAR-T manufacture (prolonged timelines, technical complexity, and high costs), we are developing an in vivo modified CAR-T platform that generates functional CAR-T cells directly within patients.

1. mRNA-LNP platform: utilizing lipid nanoparticle-formulated mRNA to reprogram T cells in vivo, by which dramatically simplifies the procedure of CAR-T preparation, and also significantly reduces the cost. Moreover, mRNA-LNP-mediated in vivo modified offers enhanced controllability and safety profiles.

2. Lentiviral in vivo delivery platform: We developed a lentiviral vector system engineered for T-cell-specific tropism, enabling efficient delivery of CAR genetic cargo into endogenous T cells, thereby achieving direct in vivo generation of CAR-T cells.